Table 3.

Summary of Changes in Thyroid Antibody Status in 20 Patients Available for Autoantibody Measurements before Initiation and during the PD-1/PD-L1 Inhibitor Therapy

Thyroid IRAE	Age, yr/Sex	Cancer	PD-1/PD-L1 inhibitor	Baseline TPO antibody titer, IU/mL	Baseline Tg antibody titer, IU/mL	Follow-up TPO antibody titer, IU/mL	Follow-up Tg antibody titer, IU/mL	Change in TPO antibody positivity	Change in Tg antibody positivity
OH	68/M	Kidney	Pembrolizumab	13.2	71.1	9.6	168.2	(−) → (+)	(−) → (+)
OH	45/F	Melanoma	Nivolumab	219.0	86.6	191.1	385.2	(+) → (+)	(−) → (+)
No-OH	67/F	Biliary	Pembrolizumab	66.6	14.6	24.4	0	(+) → (−)	(−) → (−)
No-OH	64/F	Kidney	Pembrolizumab	7.8	11.9	5.7	23.7	(−) → (−)	(−) → (−)
No-OH	67/M	Liver	Nivolumab	18.4	0	25.7	0	(−) → (−)	(−) → (−)
No-OH	62/M	Lung	Nivolumab	6.9	0	9.7	0	(−) → (−)	(−) → (−)
No-OH	59/M	Lung	Nivolumab	52.6	93.6	13.0	12.0	(+) → (−)	(−) → (−)
No-OH	45/F	Lung	Nivolumab	7.3	11.0	10.3	0	(−) → (−)	(−) → (−)
No-OH	69/M	Lung	Nivolumab	11.2	86.6	5.6	0	(−) → (−)	(−) → (−)
No-OH	63/M	Lung	Durvalumab	0	0	13.9	0	(−) → (−)	(−) → (−)
No-OH	78/M	Lung	Durvalumab	19.5	0	42.3	0	(−) → (+)	(−) → (−)
No-OH	59/M	Lung	Durvalumab	20.2	0	16.1	28.1	(−) → (−)	(−) → (−)
No-OH	68/M	Lung	Durvalumab	0	0	7.3	0	(−) → (−)	(−) → (−)
No-OH	71/M	Lung	Durvalumab	8.3	0	12.2	0	(−) → (−)	(−) → (−)
No-OH	74/M	Lung	Atezolizumab	32.1	0	12.5	10.4	(−) → (−)	(−) → (−)
No-OH	57/M	Lung	Atezolizumab	14.0	0	27.7	0	(−) → (−)	(−) → (−)
No-OH	55/M	Lung	Atezolizumab	13.5	0	12.4	0	(−) → (−)	(−) → (−)
No-OH	69/F	Lung	Atezolizumab	9.1	178.7	7.4	457.6	(−) → (−)	(+) → (+)
No-OH	37/M	Lung	Atezolizumab	13.5	0	15.8	0	(−) → (−)	(−) → (−)
Normal thyroid function	79/F	Lung	Pembrolizumab	15.5	0	15.7	11.8	(−) → (−)	(−) → (−)

PD-1, programmed cell death protein-1; PD-L1, programmed cell death protein-ligand 1; IRAE, immune-related adverse event; TPO, thyroid peroxidase; Tg, thyroglobulin; OH, overt hypothyroidism.